Prilenia and Ferrer begin Phase III trial of Huntington’s therapy

Prilenia Therapeutics and Ferrer have begun the confirmatory Phase III PRECISE-HD trial assessing pridopidine as a potential treatment for HD. The study plans to enrol 400 participants living with early to mid-stage HD. The study aims to assess pridopidine’s impact on disease progression and quality of life in HD patients. Credit: bangoland / Shutterstock.com. Prilenia Therapeutics and Ferrer have begun the confirmatory Phase III PRECISE-HD clinical trial assessing pridopidine as a potential treatment for Huntington’s disease (HD). The randomised, double-blind, placebo-controlled trial aims to further evaluate the efficacy and safety of the investigational drug pridopidine, an oral capsule taken twice…

Source: Clinical Trials Arena